Supernus Pharmaceuticals Inc. (NASDAQ:SUPN) – Equities researchers at Jefferies Group upped their Q3 2016 earnings estimates for Supernus Pharmaceuticals in a report issued on Monday. Jefferies Group analyst D. Steinberg now forecasts that the firm will post earnings per share of $0.34 for the quarter, up from their prior forecast of $0.23. Jefferies Group currently has a “Buy” rating on the stock. Jefferies Group also issued estimates for Supernus Pharmaceuticals’ Q4 2016 earnings at $0.23 EPS.

Earnings History and Estimates for Supernus Pharmaceuticals (NASDAQ:SUPN)

Separately, Zacks Investment Research raised shares of Supernus Pharmaceuticals from a “hold” rating to a “buy” rating and set a $26.00 target price on the stock in a research note on Wednesday, October 5th. Three equities research analysts have rated the stock with a hold rating and two have issued a buy rating to the company’s stock. Supernus Pharmaceuticals has a consensus rating of “Hold” and a consensus target price of $25.25.

Supernus Pharmaceuticals (NASDAQ:SUPN) traded up 3.598% during trading on Thursday, hitting $24.475. 160,877 shares of the stock traded hands. Supernus Pharmaceuticals has a one year low of $9.51 and a one year high of $26.84. The company’s 50 day moving average is $21.71 and its 200 day moving average is $20.98. The company has a market capitalization of $1211.71 billion, a P/E ratio of 48.950 and a beta of 1.86.

In other Supernus Pharmaceuticals news, CFO Gregory S. Patrick sold 2,000 shares of the stock in a transaction dated Friday, September 16th. The stock was sold at an average price of $25.00, for a total value of $50,000.00. Following the completion of the sale, the chief financial officer now directly owns 3,616 shares in the company, valued at $90,400. The transaction was disclosed in a document filed with the SEC, which is available at this link. 6.10% of the stock is owned by company insiders.

Large investors have recently added to or reduced their stakes in the stock. BlackRock Fund Advisors boosted its stake in Supernus Pharmaceuticals by 27.5% in the third quarter. BlackRock Fund Advisors now owns 3,952,348 shares of the specialty pharmaceutical company’s stock worth $97,742,000 after buying an additional 853,080 shares during the period. Vanguard Group Inc. boosted its stake in Supernus Pharmaceuticals by 10.0% in the second quarter. Vanguard Group Inc. now owns 1,956,476 shares of the specialty pharmaceutical company’s stock worth $39,854,000 after buying an additional 177,648 shares during the period. Acadian Asset Management LLC boosted its stake in Supernus Pharmaceuticals by 13.8% in the third quarter. Acadian Asset Management LLC now owns 1,737,526 shares of the specialty pharmaceutical company’s stock worth $42,967,000 after buying an additional 210,249 shares during the period. Bank of New York Mellon Corp boosted its stake in Supernus Pharmaceuticals by 2.1% in the third quarter. Bank of New York Mellon Corp now owns 1,694,026 shares of the specialty pharmaceutical company’s stock worth $41,892,000 after buying an additional 34,422 shares during the period. Finally, Fiera Capital Corp acquired a new stake in Supernus Pharmaceuticals during the second quarter worth approximately $27,544,000. Institutional investors own 97.09% of the company’s stock.

Supernus Pharmaceuticals Company Profile

Supernus Pharmaceuticals, Inc is a pharmaceutical company focused on developing and commercializing products for the treatment of central nervous system (CNS) diseases. The Company offers products for the treatment of epilepsy, which include extended-release oxcarbazepine (Oxtellar XR) and extended-release topiramate (Trokendi XR).

5 Day Chart for NASDAQ:SUPN

Receive News & Stock Ratings for Supernus Pharmaceuticals Inc. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Supernus Pharmaceuticals Inc. and related stocks with our FREE daily email newsletter.